TY - T1的现实世界anti-IL的有效性-5/5R therapies is independent of co-eligibility for anti-IgE therapy JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00166-2021 VL - 57 IS - 6 SP - 2100166 AU - Hearn, Andrew P. AU - Hug, Oliver D. AU - Somani, Ziana A. AU - Kavanagh, Joanne AU - d'Ancona, Grainne AU - Roxas, Cris AU - Green, Linda AU - Thomson, Louise AU - Fernandes, Mariana AU - Kent, Brian D. AU - Dhariwal, Jaideep AU - Nanzer, Alexandra M. AU - Jackson, David J. Y1 - 2021/06/01 UR - //www.qdcxjkg.com/content/57/6/2100166.abstract N2 - Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting interleukin (IL)-5 and IL-5R, respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3].In a real-world setting, the clinical response to the anti-IL-5/5R mAbs mepolizumab and benralizumab in patients with severe eosinophilic asthma is independent of co-eligibility with the anti-IgE mAb omalizumab https://bit.ly/2NfAitP ER -